近年來糖尿病腎病引起慢性心衰的發(fā)病速度快速增長,目前還缺乏有效藥物。finerenone是新一代口服非甾體類鹽皮質激素受體拮抗劑,阻斷醛甾酮導致的鹽皮質激素受體過度激活產生的有害影響,可用于嚴重腎功能損害的患者。多項臨床試驗研究表明finerenone具有良好的安全性和有效性。主要從finerenone的藥物概況、相關背景、合成路線、作用機制、藥理作用和臨床研究等方面進行介紹。

Recently, the disease developing speed of chronic heart failure induced by diabetic nephropathy is increasing rapidly, but now there is lack of effective drugs. finerenone is a new generation of oral non steroidal mineralcorticoid recept antagonist, and can block the harmful effects of the excessive activation of aldehydes and ketones, and can be used for patients with severe renal damage. Many clinical studies show that finerenone has a good safety and effectiveness. The drug situation, background, route of synthesis, mechanism and pharmacological action, and clinical trials researches of finerenone are reviewed in this paper.